RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia

to related objects

Abstract: Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of early childhood characterized by mutations activating RAS signaling. Established clinical and genetic markers fail to fully recapitulate the clinical and biological heterogeneity of this disease. Here we report DNA methylome analysis and mutation profiling of 167 JMML samples. We identify three JMML subgroups with unique molecular and clinical characteristics. The high methylation group (HM) is characterized by somatic PTPN11 mutations and poor clinical outcome. The low methylation group is enriched for somatic NRAS and CBL mutations, as well as for Noonan patients, and has a good prognosis. The intermediate methylation group (IM) shows enrichment for monosomy 7 and somatic KRAS mutations. Hypermethylation is associated with repressed chromatin, genes regulated by RAS signaling, frequent co-occurrence of RAS pathway mutations and upregulation of DNMT1 and DNMT3B, suggesting a link between activation of the DNA methylation machinery and mutational patterns in JMML

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch
Notes
Nature communications. - 8 (2017) , 2126, ISSN: 2041-1723

Event
Veröffentlichung
(where)
Freiburg
(who)
Universität
(when)
2021
Creator

DOI
10.1038/s41467-017-02177-w
URN
urn:nbn:de:bsz:25-freidok-1755958
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:24 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

Time of origin

  • 2021

Other Objects (12)

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

Hochschulschrift

Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien

Extrazelluläre Effekte des Ca2+-bindenden Proteins S100A1 : grundlegende Experimente zur Morphologie und Funktion neonataler Kardiomyozyten in Abhängigkeit der Kulturbedingungen

Hochschulschrift

Extrazelluläre Effekte des Ca2+-bindenden Proteins S100A1 : grundlegende Experimente zur Morphologie und Funktion neonataler Kardiomyozyten in Abhängigkeit der Kulturbedingungen

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum

RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia

RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia

Epigenetic therapy of cancer : preclinical models and treatment approaches

Aufsatzsammlung

Epigenetic therapy of cancer : preclinical models and treatment approaches

Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren

Hochschulschrift

Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren

DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie

Hochschulschrift

DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie

Das Verbundprojekt "Personalisierte Medizin für die Onkologie" (PM4Onco) als Teil der Medizininformatik-Initiative (MII) : = The collaborative project "Personalized medicine for oncology" (PM4Onco) as part of the Medical Informatics Initiative (MII)

Das Verbundprojekt "Personalisierte Medizin für die Onkologie" (PM4Onco) als Teil der Medizininformatik-Initiative (MII) : = The collaborative project "Personalized medicine for oncology" (PM4Onco) as part of the Medical Informatics Initiative (MII)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study

Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia

Related objects